Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Hangzhou Tigermed Consulting Co., Ltd. Class H ( (HK:3347) ) just unveiled an announcement.
Hangzhou Tigermed Consulting Co., Ltd. has announced proposed amendments to its Articles of Association and corporate governance rules to align with the latest legal and regulatory standards. These changes aim to enhance the company’s operational efficiency and governance structure, reflecting its commitment to standardized operations and improved shareholder relations. The proposed amendments require shareholder approval and are designed to refine the company’s governance framework, thereby potentially strengthening its market position and stakeholder trust.
The most recent analyst rating on (HK:3347) stock is a Sell with a HK$37.00 price target. To see the full list of analyst forecasts on Hangzhou Tigermed Consulting Co., Ltd. Class H stock, see the HK:3347 Stock Forecast page.
More about Hangzhou Tigermed Consulting Co., Ltd. Class H
Hangzhou Tigermed Consulting Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, focusing on providing clinical trial services and consulting for the pharmaceutical and biotechnology industries. The company is listed on the Stock Exchange of Hong Kong and is committed to enhancing its corporate governance and operational standards.
Average Trading Volume: 4,878,203
Technical Sentiment Signal: Buy
Current Market Cap: HK$55.09B
See more insights into 3347 stock on TipRanks’ Stock Analysis page.